Pharmaceutical heavyweight Novo Nordisk is under pressure: a leadership dispute, skeptical analysts and the expensive Metsera takeover offer are causing unrest among investors.
• Novo Nordisk: What concerns investors and analysts
• Investors react cautiously to takeover offer
• Novo Nordisk shares under pressure
Board crisis
An open power struggle between the supervisory board and the Novo Nordisk Foundation as the majority shareholder has recently led to an unprecedented leadership tremor at Novo Nordisk. As reported last week, supervisory board chairman Helge Lund and several independent members resigned after disagreements over the future composition of the supervisory body escalated. The group has now called an extraordinary general meeting for November 14th at which the new appointment will be decided. This corporate governance crisis comes at the worst possible time, as the company is already facing regulatory challenges in its most important market.
Analysts are becoming more cautious
Given the current uncertainties, analysts have also become increasingly skeptical. The analysts at Jefferies positioned themselves particularly clearly, drastically lowering the price target from NOK 415 to NOK 290 and rating the share as “underperform”. The investment bank cites the impending patent expiry of the semaglutide franchise by 2031/2032 as the main reason, which generally leads to more cautious assessments in the industry before such “patent cliffs”. UBS, on the other hand, is sticking to its “neutral” rating, but notes that investors are currently critically questioning management’s experience in the challenging US market. The current mix of regulatory challenges and internal management problems makes a reliable price forecast difficult.
Solid fundamentals and takeover fantasy?
Despite the current challenges, Novo Nordisk remains one of the world’s leaders in diabetes, obesity and cardiovascular disease. Long-term investors point to the company’s strong market position, particularly in the growing market for obesity medications, but see the current management problems as a potential risk to the implementation of the company’s strategy.
In addition, Novo Nordisk wants to further secure its leading position in the booming market for weight loss medications – and is reaching out to the US biotech company Metsera, which was originally supposed to be taken over by its competitor Pfizer.
According to a statement on Thursday, Novo Nordisk is offering $56.50 per Metsera share, which corresponds to a total volume of around $6.5 billion. Additionally, up to $21.25 per share could be added upon reaching certain milestones. This means that the Danish offer significantly exceeds Pfizer’s previous offer, which was $47.50 in cash – plus a maximum of $22.50 in contingency payments.
Metsera officially described Novo Nordisk’s offer as financially superior. Under the terms of the existing merger agreement, Pfizer now has four business days to follow up and adjust the terms.
However, Novo Nordisk investors reacted to the takeover offer with mixed feelings. The shares in Copenhagen fell by 3.63 percent to 322.70 Danish crowns on Thursday after the offer was published. On Friday it fell by a further 2.09 percent to a closing price of DKK 315.95.
What will happen next for Novo Nordisk shares – and whether the takeover of Metsera will be successful – remains to be seen.
Editorial team finanzen.net
This text is for informational purposes only and does not constitute an investment recommendation. finanzen.net GmbH excludes any claims for recourse.
By the way: Pfizer and other US stocks can even be traded on finanzen.net ZERO until 11 p.m. (without order fees, plus spreads). Open a depot now for free and secure a new customer bonus!
Selected leverage products on Metsera
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Metsera
The leverage must be between 2 and 20
Advertising